盐酸文拉法辛缓释片治疗抑郁焦虑共病的疗效分析

Curative effects of vanlafaxine hydrochloride in treating co-morbidity of depression and anxiety

目的分析盐酸文拉法辛缓释片在治疗抑郁焦虑共病中的疗效。方法选择2014-08—2016-08我院收治的160例抑郁焦虑共病患者,按照随机数字表法分为观察组(n=80)和对照组(n=80),对照组给予盐酸帕罗西汀片口服,观察组给予盐酸文拉法辛缓释片口服,8周后观察分析2组患者临床疗效。结果治疗4周末与8周末时,2组患者汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)评分较治疗前均有明显降低(P<0.05);治疗4周末与8周末时,观察组HAMD、HAMA评分显著低于对照组(P<0.05);治疗8周末,观察组总有效率显著高于对照组(χ2=4.55,P<0.05),总不良发生率明显低于对照组(χ2=4.29,P<0.05)。结论盐酸文拉法辛缓释片可以快速缓解抑郁焦虑共病症状,临床疗效显著。

Objective To analyze the curative effects of vanlafaxine hydrochloride in treating the co-morbidity of depression and anxiety. Methods 160 cases of patients with co-morbidity of depression and anxiety admitted and treated in our hospital from August 2014 to August 2016 were randomly divided into observation group（n = 80） and control group（n = 80）. Patients in the control group were given paroxetine hydrochloride oral administration, while patients in the observation group were given vaulafax ine hydrochloride oral administration. The clinical effects 8 months after the treatment were observed and analyzed. Results At the end of 4 weeks after treatment and the end of 8 months after treatment, HAMD and HAMA scores were significantly lower than those of before treatment in both groups （P〈0.05）. At the end of 4 weeks after treatment and the end of 8 months after treatment,HAMD scores and HAMA scores in the observation group were significantly lower than the contrast group （P 〈 0.05）. At the end of 8 weeks after treatment, the total effective rate in the observation group was significantly higher than the con trol group （x^2 = 4.55, P 〈0.05）. The total adverse reaction occurrence rate in the observation group was significant lower than the control group （x^2 =4.55,P〈0.05）. Conclusion Vanlafaxine hydrochloride can quickly relieve the co-morbidity of depression and anxiety with significant curative effects.